Avicanna Inc AVCNF

Q3 FINS Review (2 / 5 stars)

[WolfOakville]

"Expect additional raises, more dilution, and Wolf to stay on the sidelines."

Click for full review

[Dagreedyanalyst]

This made my day. Thank you for confirming that someone important and funded enough is naked shorting this stock that got this clown to write this none sense report. Happy dispute essentially all of your points except its a waste of time. The Company is now debt free so risk for dilution is very low. This is not a 120 year old company you only look at metrics, the reality is this: 1: Revenue is

[WolfOakville]

Let's re-visit this in 6 months. Nonsense is one word and contains no "e" sunshine.  How will they service their payables with their cash situation and still burning $.  organic growth in the quarter was down double digits. 1x revenue doesn't matter given the above.   

[Dagreedyanalyst]

1 x revenue for a 57% GM margin, IP/pharma company, you are not assessing an MJ stock though thats the picture you would want to paint. This company is still in early stages and is 25M market cap not a blue chip so your metrics are inconsistent with the size and scope of the Company. Y-Y growth has been massive and they are showing amaizng signals across IP, margins and growth. The fact that you

[WolfOakville]

GFY whiner.